Dr. Jesus G Berdeja, MD
Claim this profileTennessee Oncology
Expert in Multiple Myeloma
Expert in Plasma Cell Neoplasms
19 reported clinical trials
25 drugs studied
About Jesus G Berdeja, MD
Education:
- Obtained MD from the University of Texas Southwestern Medical School, graduating in 2001.
- Completed Residency in Internal Medicine at Vanderbilt University Medical Center in 2004.
- Finished Fellowship in Hematology/Oncology at Vanderbilt University Medical Center in 2007.
Experience:
- Director of Myeloma Research and Senior Vice President of Clinical Research at Tennessee Oncology.
- Professor of Medicine at Vanderbilt University Medical Center.
Area of expertise
1Multiple Myeloma
Global Leadert(4;14) positive
GOF mutation in MMSET positive
2Plasma Cell Neoplasms
Global Leadert(4;14) positive
GOF mutation in MMSET positive
Affiliated Hospitals
Clinical Trials Jesus G Berdeja, MD is currently running
CFT7455
for Lymphoma
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Recruiting1 award Phase 1 & 210 criteria
Iberdomide + Daratumumab vs. Bortezomib
for Multiple Myeloma
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Recruiting2 awards Phase 3
More about Jesus G Berdeja, MD
Clinical Trial Related2 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Jesus G Berdeja, MD has experience with
- Dexamethasone
- Daratumumab
- Pomalidomide
- Bortezomib
- Carfilzomib
- Iberdomide
Breakdown of trials Jesus G Berdeja, MD has run
Multiple Myeloma
Plasma Cell Neoplasms
Tumors
Immunoproliferative Disorders
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jesus G Berdeja, MD specialize in?
Jesus G Berdeja, MD focuses on Multiple Myeloma and Plasma Cell Neoplasms. In particular, much of their work with Multiple Myeloma has involved t(4;14) positive patients, or patients who are GOF mutation in MMSET positive.
Is Jesus G Berdeja, MD currently recruiting for clinical trials?
Yes, Jesus G Berdeja, MD is currently recruiting for 7 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Jesus G Berdeja, MD has studied deeply?
Yes, Jesus G Berdeja, MD has studied treatments such as Dexamethasone, Daratumumab, Pomalidomide.
What is the best way to schedule an appointment with Jesus G Berdeja, MD?
Apply for one of the trials that Jesus G Berdeja, MD is conducting.
What is the office address of Jesus G Berdeja, MD?
The office of Jesus G Berdeja, MD is located at: Tennessee Oncology, Nashville, Tennessee 37203-1625 United States. This is the address for their practice at the Tennessee Oncology.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.